1751 RIVER RUN, FORT WORTH, TX
Actuate Therapeutics Shows Positive Phase 2 Results for Elraglusib in Pancreatic Cancer at ASCO GI 2026
Actuate Therapeutics Enters $100 Million At The Market Issuance Agreement
Other Events
Announces Pricing of $15.0 Million Public Offering of Common Stock
News, Securities Holder Rights or Indentures, Material Contracts
Transcript of Key Opinion Leader Event
Elraglusib Phase 2 Data Shows Promise in Pancreatic Cancer at ASCO 2025
Shareholder votes
FY 2025
Q3
Q1
FY 2024
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Free Writing Prospectus
Amended Form D Notice of Exempt Offering of Securities